Page last updated: 2024-08-24

irinotecan and Ependymoma

irinotecan has been researched along with Ependymoma in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	1 (25.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fujisaki, H; Hara, J; Okada, K; Osugi, Y; Tanaka, C; Yamasaki, K	1
Boyett, JM; Fangusaro, J; Friedman, HS; Gajjar, A; Gilbertson, RJ; Goldman, S; Gururangan, S; Kun, LE; McLendon, R; Onar-Thomas, A; Packer, RJ; Vajapeyam, S; Young Poussaint, T	1
Bigner, DD; Coggins, CA; Colvin, OM; Elion, GB; Friedman, HS; Hare, CB; Houghton, PJ; Keir, S	1
Beason, R; Bottom, K; Eastwood, J; Friedman, AH; Friedman, HS; Gururangan, S; McLendon, RE; Miller, LL; Tourt-Uhlig, S; Turner, CD; Watral, M	1

Trials

3 trial(s) available for irinotecan and Ependymoma

Article	Year
Phase I study of bevacizumab plus irinotecan in pediatric patients with recurrent/refractory solid tumors. Japanese journal of clinical oncology, 2013, Volume: 43, Issue:11 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Central Nervous System Neoplasms; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Neoplasm; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Maximum Tolerated Dose; Medulloblastoma; Neoplasm Recurrence, Local; Neoplasms; Rhabdomyosarcoma; Treatment Outcome; Young Adult	2013
Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro-oncology, 2012, Volume: 14, Issue:11 Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Disease-Free Survival; Ependymoma; Female; Humans; Immunohistochemistry; Irinotecan; Kaplan-Meier Estimate; Male; Neoplasm Recurrence, Local; Salvage Therapy; Young Adult	2012
Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. Neuro-oncology, 2002, Volume: 4, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Astrocytoma; Brain Neoplasms; Camptothecin; Child; Child, Preschool; Drug Administration Schedule; Ependymoma; Female; Glioblastoma; Glioma; Humans; Irinotecan; Magnetic Resonance Imaging; Male; Medulloblastoma; Topoisomerase Inhibitors	2002

Other Studies

1 other study(ies) available for irinotecan and Ependymoma

Article	Year
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6 Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmustine; Child; Cyclophosphamide; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous	1998

Article

Year

Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.

Cancer chemotherapy and pharmacology, 1998, Volume: 41, Issue:6

Topics: Adult; Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Busulfan; Camptothecin; Carmustine; Child; Cyclophosphamide; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Ependymoma; Female; Glioma; Humans; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Topoisomerase I Inhibitors; Transplantation, Heterologous

1998